Citi cuts Ypsomed to 'neutral' after strong share-price run
** Citi cuts Swiss drug-delivery device maker Ypsomed YPSN.S to "neutral" from "buy" after the stock's recent re-rating
** Shares are up 21% over the last month and 34% year-to-date
** Citi remains positive on Ypsomed's medium-term growth prospects, but sees a more balanced risk-reward profile at the current valuation, with few near-term catalysts before FY 2026/27 results next May
** It continues to view Ypsomed as a "high-quality asset" thanks to its attractive exposure to biologics, biosimilars and incretin therapies
** Following the company's H1 results and guidance hike, Citi increases its EPS estimates by 3-5% for fiscal years 2026/27-2030/31
** It also raises its PT to CHF 450 ($537) from CHF 425
($1 = 0.8384 Swiss francs)